Colin M. Tice
Research Subjects
Colin M. Tice has a total of 133 co-authors. Here are the top co-authors by number of shared publications:
Suresh B. Singh
Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, USA
11 shared publicationsDavid A. Claremon
Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, USA
10 shared publicationsGerard M. McGeehan
Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, USA
10 shared publicationsJoan Guo
Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, USA
9 shared publications- Wei Zhao
Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, PA 19034, USA
9 shared publications - Yuri Bukhtiyarov
Vitae Pharmaceuticals, 502 West Office Center Drive, Fort Washington, Pennsylvania 19034, United States
9 shared publications
Latest Publications
- 27 November 2019
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 6 (2) , 302-312
Tight-Binding Hydroxypyrazole HIV-1 Nef Inhibitors Suppress Viral Replication in Donor Mononuclear Cells and Reverse Nef-Mediated MHC-I Downregulation
The HIV-1 Nef accessory factor is critical to the viral life cycle in vivo and promotes immune escape of infected cells via downregulation of cell-surface MHC-I. Previously, we discovered small molecules that bind directly to Nef and block many of its functions, including enhancement of viral infectivity and replication in T cell lines. These compounds also restore cell-surface MHC-I expression in HIV-infected CD4 T cells from AIDS patients, enabling recognition and killing by autologous cytotoxic T lymphocytes (CTLs). In this study, we describe the synthesis and evaluation of a diverse set of analogs based on the original hydroxypyrazole Nef inhibitor core. All analogs were screened for the interaction with recombinant HIV-1 Nef by surface plasmon resonance (SPR) and for antiretroviral activity in TZM-bl reporter cells infected with HIV-1. Active analogs were ranked on the basis of an activity score that integrates three aspects of the SPR data (affinity, residence time, and extent of binding) with antiretroviral activity. The top scoring compounds bound tightly to Nef by SPR, with KD values in the low nM to pM range, and displayed very slow dissociation from their Nef target. These analogs also suppressed HIV-1 replication in donor peripheral blood mononuclear cells (PBMCs) with IC50 values in the 1–10 nM range without cytotoxicity, inhibited Nef-mediated IL-2-inducible tyrosine kinase (Itk) and hematopoietic cell kinase (Hck) activation, and rescued MHC-I downregulation in a Nef-transfected T cell line. The development of Nef inhibitors based on the structure–activity relationships defined here has promise as a new approach to antiretroviral therapy that includes a path to eradication of HIV-infected cells via the adaptive immune response.
- 27 November 2019
- Published by American Chemical Society (ACS) in ACS Infectious Diseases
- Vol. 6 (2) , 302-312
Tight-Binding Hydroxypyrazole HIV-1 Nef Inhibitors Suppress Viral Replication in Donor Mononuclear Cells and Reverse Nef-Mediated MHC-I Downregulation
The HIV-1 Nef accessory factor is critical to the viral life cycle in vivo and promotes immune escape of infected cells via downregulation of cell-surface MHC-I. Previously, we discovered small molecules that bind directly to Nef and block many of its functions, including enhancement of viral infectivity and replication in T cell lines. These compounds also restore cell-surface MHC-I expression in HIV-infected CD4 T cells from AIDS patients, enabling recognition and killing by autologous cytotoxic T lymphocytes (CTLs). In this study, we describe the synthesis and evaluation of a diverse set of analogs based on the original hydroxypyrazole Nef inhibitor core. All analogs were screened for the interaction with recombinant HIV-1 Nef by surface plasmon resonance (SPR) and for antiretroviral activity in TZM-bl reporter cells infected with HIV-1. Active analogs were ranked on the basis of an activity score that integrates three aspects of the SPR data (affinity, residence time, and extent of binding) with antiretroviral activity. The top scoring compounds bound tightly to Nef by SPR, with KD values in the low nM to pM range, and displayed very slow dissociation from their Nef target. These analogs also suppressed HIV-1 replication in donor peripheral blood mononuclear cells (PBMCs) with IC50 values in the 1–10 nM range without cytotoxicity, inhibited Nef-mediated IL-2-inducible tyrosine kinase (Itk) and hematopoietic cell kinase (Hck) activation, and rescued MHC-I downregulation in a Nef-transfected T cell line. The development of Nef inhibitors based on the structure–activity relationships defined here has promise as a new approach to antiretroviral therapy that includes a path to eradication of HIV-infected cells via the adaptive immune response.
- 30 November 2017
- Published by American Chemical Society (ACS)
- p. 195-216
ROR-gamma-T Modulators for Th17-Driven Diseases: Progress Into the Clinic
- 30 November 2017
- Published by American Chemical Society (ACS)
- p. 195-216
ROR-gamma-T Modulators for Th17-Driven Diseases: Progress Into the Clinic
- 1 October 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (20) , 5044-5050
Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core
- 1 October 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (20) , 5044-5050
Brain penetrant liver X receptor (LXR) modulators based on a 2,4,5,6-tetrahydropyrrolo[3,4-c]pyrazole core
- 1 September 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (17) , 4157-4164
Non-canonical modulators of nuclear receptors
- 1 September 2016
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 26 (17) , 4157-4164
Non-canonical modulators of nuclear receptors
- Top Cited PapersOpen Access
- 9 June 2016
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 11 (9) , 831-834
The utilization of spirocyclic scaffolds in novel drug discovery
(2016). The utilization of spirocyclic scaffolds in novel drug discovery. Expert Opinion on Drug Discovery: Vol. 11, No. 9, pp. 831-834.
- 9 June 2016
- Published by Taylor & Francis in Expert Opinion on Drug Discovery
- Vol. 11 (9) , 831-834
Top Cited PapersOpen AccessThe utilization of spirocyclic scaffolds in novel drug discovery
(2016). The utilization of spirocyclic scaffolds in novel drug discovery. Expert Opinion on Drug Discovery: Vol. 11, No. 9, pp. 831-834.
- 29 March 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (7) , 3264-3271
Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) β Agonist
This article describes the application of Contour to the design and discovery of a novel, potent, orally efficacious liver X receptor β (LXRβ) agonist (17). Contour technology is a structure-based drug design platform that generates molecules using a context perceptive growth algorithm guided by a contact sensitive scoring function. The growth engine uses binding site perception and programmable growth capability to create drug-like molecules by assembling fragments that naturally complement hydrophilic and hydrophobic features of the protein binding site. Starting with a crystal structure of LXRβ and a docked 2-(methylsulfonyl)benzyl alcohol fragment (6), Contour was used to design agonists containing a piperazine core. Compound 17 binds to LXRβ with high affinity and to LXRα to a lesser extent, and induces the expression of LXR target genes in vitro and in vivo. This molecule served as a starting point for further optimization and generation of a candidate which is currently in human clinical trials for treating atopic dermatitis.
- 29 March 2016
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 59 (7) , 3264-3271
Discovery of a Novel, Orally Efficacious Liver X Receptor (LXR) β Agonist
This article describes the application of Contour to the design and discovery of a novel, potent, orally efficacious liver X receptor β (LXRβ) agonist (17). Contour technology is a structure-based drug design platform that generates molecules using a context perceptive growth algorithm guided by a contact sensitive scoring function. The growth engine uses binding site perception and programmable growth capability to create drug-like molecules by assembling fragments that naturally complement hydrophilic and hydrophobic features of the protein binding site. Starting with a crystal structure of LXRβ and a docked 2-(methylsulfonyl)benzyl alcohol fragment (6), Contour was used to design agonists containing a piperazine core. Compound 17 binds to LXRβ with high affinity and to LXRα to a lesser extent, and induces the expression of LXR target genes in vitro and in vivo. This molecule served as a starting point for further optimization and generation of a candidate which is currently in human clinical trials for treating atopic dermatitis.
- Top Cited PapersOpen Access
- 1 August 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (16) , 3673-3682
The use of spirocyclic scaffolds in drug discovery
- 1 August 2014
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 24 (16) , 3673-3682
Top Cited PapersOpen AccessThe use of spirocyclic scaffolds in drug discovery
- 28 May 2014
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (17) , 7182-7205
The Medicinal Chemistry of Liver X Receptor (LXR) Modulators
LXRs have been of interest as targets for the treatment of atherosclerosis for over a decade. In recent years, LXR modulators have also garnered interest for potential use in the treatment of inflammation, Alzheimer’s disease (AD), dermatological conditions, hepatic steatosis, and oncology. To date, no LXR modulator has successfully progressed beyond phase I clinical trials. In this Perspective, we summarize published medicinal chemistry efforts in the context of the available crystallographic data, druglikeness, and isoform selectivity. In addition, we discuss the challenges that need to be overcome before an LXR modulator can reach clinical use.
- 28 May 2014
- Published by American Chemical Society (ACS) in Journal of Medicinal Chemistry
- Vol. 57 (17) , 7182-7205
The Medicinal Chemistry of Liver X Receptor (LXR) Modulators
LXRs have been of interest as targets for the treatment of atherosclerosis for over a decade. In recent years, LXR modulators have also garnered interest for potential use in the treatment of inflammation, Alzheimer’s disease (AD), dermatological conditions, hepatic steatosis, and oncology. To date, no LXR modulator has successfully progressed beyond phase I clinical trials. In this Perspective, we summarize published medicinal chemistry efforts in the context of the available crystallographic data, druglikeness, and isoform selectivity. In addition, we discuss the challenges that need to be overcome before an LXR modulator can reach clinical use.
- 16 August 2011
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 2 (10) , 747-751
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility
Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with a (R)-(tetrahydropyran-3-yl)methyl group and utilization of a different attachment point led to the identification of clinical candidate 9. This compound demonstrated excellent selectivity over related and unrelated off-targets, >15% oral bioavailability in three species, oral efficacy in a double transgenic rat model of hypertension, and good exposure in humans.
- 16 August 2011
- Published by American Chemical Society (ACS) in ACS Medicinal Chemistry Letters
- Vol. 2 (10) , 747-751
Discovery of VTP-27999, an Alkyl Amine Renin Inhibitor with Potential for Clinical Utility
Structure guided optimization of a series of nonpeptidic alkyl amine renin inhibitors allowed the rational incorporation of additional polar functionality. Replacement of the cyclohexylmethyl group occupying the S1 pocket with a (R)-(tetrahydropyran-3-yl)methyl group and utilization of a different attachment point led to the identification of clinical candidate 9. This compound demonstrated excellent selectivity over related and unrelated off-targets, >15% oral bioavailability in three species, oral efficacy in a double transgenic rat model of hypertension, and good exposure in humans.
- 15 August 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (16) , 4836-4843
Biphenyl/diphenyl ether renin inhibitors: Filling the S1 pocket of renin via the S3 pocket
- 15 August 2011
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 21 (16) , 4836-4843
Biphenyl/diphenyl ether renin inhibitors: Filling the S1 pocket of renin via the S3 pocket